GlassScriptPhysician profile
Ashley Desrocher
NPI 1104147792
$7,805.47
in general payments reported to CMS, 2019-2025
40 companies · $953 in 2025
The $953 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,787 · 2022: $1,278 · 2023: $2,247 · 2024: $1,541 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,904 · Honoraria: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,903.50 |
| Honoraria | $837.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $1,014.40 | 2023-2024 | Elfabrio |
| Glaxosmithkline, LLC. | $758.88 | 2021-2024 | Nucala, Benlysta |
| Astrazeneca Pharmaceuticals LP | $617.44 | 2021-2024 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $479.90 | 2022-2025 | Jardiance, Spevigo |
| Janssen Scientific Affairs, LLC | $409.76 | 2023-2025 | Tremfya, Xarelto, Stelara |
| Grifols USA, LLC | $403.59 | 2021-2023 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Tg Therapeutics, INC. | $382.64 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $314.33 | 2021-2022 | |
| Genentech USA, INC. | $275.85 | 2021-2023 | Tecentriq, Activase |
| Abbvie INC. | $275.56 | 2021-2023 | |
| Medtronic, INC. | $271.90 | 2022-2025 | Signia, Venaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $242.57 | 2021-2023 | Entyvio, Gattex |
| Paratek Pharmaceuticals, INC. | $206.88 | 2021-2022 | |
| Biogen, INC. | $206.82 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Idorsia Pharmaceuticals US INC | $199.28 | 2023-2024 | Quviviq |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $144.46 | 2022-2023 | Amvuttra |
| Abbott Laboratories | $136.62 | 2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $129.53 | 2023-2024 | |
| Insulet Corporation | $129.09 | 2022 | |
| Amag Pharmaceuticals, INC. | $118.15 | 2021 | |
| Amgen INC. | $114.91 | 2021-2024 | Krystexxa |
| Pfizer INC. | $106.45 | 2021-2025 | |
| Janssen Biotech, INC. | $101.32 | 2021-2022 | |
| Lundbeck LLC | $98.12 | 2021-2023 | Vyepti |
| Insmed, INC. | $80.88 | 2024-2025 | Arikayce |
| Daiichi Sankyo INC. | $71.09 | 2021 | |
| Sanofi-Aventis U.S. LLC | $66.62 | 2023 | |
| Scynexis, INC. | $60.01 | 2022 | |
| Gilead Sciences, INC. | $59.50 | 2025 | Livdelzi |
| Genzyme Corporation | $57.25 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $49.02 | 2025 | |
| Alkermes, INC. | $39.34 | 2022 | |
| Dexcom, INC. | $35.07 | 2025 | Dexcom G6 Transmitter |
| Sandoz INC. | $31.06 | 2023 | |
| Alexion Pharmaceuticals, INC. | $23.44 | 2023 | Soliris |
| Fresenius Kabi USA, LLC | $22.27 | 2022 | |
| Organon LLC | $20.00 | 2021 | |
| Pharmacosmos Therapeutics INC. | $18.60 | 2023 | Monoferric |
| La Jolla Pharmaceutical Company | $17.66 | 2021 | |
| American Regent | $15.21 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Desrocher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.